| Title |
Goal-directed therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a prospective observational study
|
|---|---|
| Published in |
Clinical and Translational Oncology, September 2018
|
| DOI | 10.1007/s12094-018-1944-y |
| Pubmed ID | |
| Authors |
N. Esteve-Pérez, A. Ferrer-Robles, G. Gómez-Romero, D. Fabián-Gonzalez, M. Verd-Rodriguez, L. C. Mora-Fernandez, J. J. Segura-Sampedro, S. Tejada-Gavela, R. Morales-Soriano |
| Abstract |
Cytoreductive surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in peritoneal carcinomatosis treatment causes significant hemodynamic, metabolic, and hematological alterations. Studies on the anesthetic intraoperative management are heterogeneous and scarce. There is a great heterogeneity in the anesthetic management of CRS and HIPEC. The aim of this study is to analyze perioperative hemodynamic goal-directed management and to evaluate the complications arisen until the seventh postoperative day. Prospective, observational study of all CRS and HIPEC patients from March 2014 to May 2017. Hemodynamic and clinical parameters were registered during surgery and the first 3 postoperative days. We correlated intraoperative data with the postoperative course until the seventh day. A total of 92 patients were included in the study (age 58.5 ± 10.9 years, 47% colorectal carcinoma, and 38% ovarian carcinoma). Peritoneal Carcinomatosis Index (PCI) (median and ranges) was 10 [0-39]. Cardiac Index (CI) 3.15 l/min-1/m-2 [1.79-5.60]) and Systolic Volume Variation (SVV) (10% [3%-17%]) remained within the values of normality in all surgery phases. A large difference was observed between the minimum and maximum ranges of fluid therapy administered (median 9.8 ml/kg/h [5.3-24.3]), showing a great interindividual variation in the fluids requirement. A direct relationship was observed between PCI and surgery duration, fluid therapy, and intraoperative transfusion percentage (p < 0.02). There is a great variability in the intraoperative fluid therapy needs of the patients. SVV monitoring makes it possible to adjust the fluid therapy needs in each surgery phase. The use of a hemodynamic goal-directed anesthetic protocol in CRS and HIPEC enables to individually adjust the fluid therapy, avoiding over-hydration and ensuring hemodynamic stability in all surgery phases. |
X Demographics
The data shown below were collected from the profiles of 29 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 16 | 55% |
| Australia | 1 | 3% |
| Switzerland | 1 | 3% |
| Unknown | 11 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 21 | 72% |
| Practitioners (doctors, other healthcare professionals) | 4 | 14% |
| Scientists | 3 | 10% |
| Unknown | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 55 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 15% |
| Student > Ph. D. Student | 6 | 11% |
| Student > Bachelor | 6 | 11% |
| Other | 4 | 7% |
| Student > Doctoral Student | 3 | 5% |
| Other | 8 | 15% |
| Unknown | 20 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 45% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Nursing and Health Professions | 2 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Business, Management and Accounting | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 21 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2023.
All research outputs
#1,659,183
of 25,732,188 outputs
Outputs from Clinical and Translational Oncology
#45
of 1,476 outputs
Outputs of similar age
#33,943
of 349,100 outputs
Outputs of similar age from Clinical and Translational Oncology
#1
of 24 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,476 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 349,100 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.